New York Post
15 Nov 2026, 17:43 UTC · 1d ago
CVS says GLP-1s save money when priced below $350 per month
Impact · against what's priced in
The CVS data creates a concrete headwind for GLP-1 manufacturers by quantifying the pricing gap (current $617-$766 vs. break-even $350) required to maintain employer coverage. This increases the probability of the bear case for Eli Lilly regarding pricing power and volume persistence, while providing a similar negative catalyst for Novo Nordisk.
- LLY−0.40
Challenges what's priced in
- The price assumes
The bear case that GLP-1 concentration risk and competitive pressure... will compress margins
The price already considers a bear case for margin compression, but the CVS data quantifies a specific catalyst: a required price cut of ~44-54% to reach a break-even point for plan sponsors, alongside 14% of companies already dropping coverage for 2027.
What LLY's price assumes · Sep 10

Search tags




